Navigation Links
Aratana Therapeutics Completes $15 Million Series B Financing
Date:12/7/2011

KANSAS CITY, Kan., Dec. 7, 2011 /PRNewswire/ -- Aratana Therapeutics, an animal health company developing innovative medicines for companion animals, announced today the closing of a $15 million Series B financing, bringing the total capital raised since Aratana was launched earlier this year to $31 million.

In addition to Aratana's Series A investors – MPM Capital, Avalon Ventures and Cultivian Ventures – new investors include the Ewing Marion Kauffman Foundation and others. 

The proceeds from the Series B financing will be used to expand the rich pipeline of innovative products that the company has already acquired.  The additional resources allow for a more aggressive approach to in-license and develop novel medicines for dogs and cats. 

"We are extremely pleased that the investment community has responded so positively to our unique approach to veterinary drug development and our focus on delivering innovative, leading-edge products to meet previously unmet or under-served needs in companion animal medicine," said Dr. Linda Rhodes, CEO of Aratana Therapeutics. "It is an endorsement of our strategy of identifying and developing compounds from human pharmaceutical and biotech companies and bringing approved products to the animal health market via out-licensing or partnering with major animal health companies."

Dr. Steven St. Peter, Aratana board chairman and managing director at MPM Capital, explained, "Everything about Aratana is innovative, from how we envisioned and started the company to our approach to drug development and how we involve new investors. Our investors share our vision and enthusiasm, and their support, along with the commitment of Aratana's board of directors, senior leadership and staff, are making our vision a reality."

About Aratana Therapeutics                                                                                                      

Aratana Therapeutics is an animal health drug development company uniquely positioned to deliver high quality new medicines for unmet needs in animal health. Aratana licenses and develops proprietary, patent-protected compounds acquired from human pharmaceutical and biotechnology companies and then out-licenses to or partners with major animal health companies for commercialization. For more information, please visit www.aratanatherapeutics.com.

CONTACT: David K. Rosen, DVM
President and COO
Aratana Therapeutics, Inc.
913-951-2130
drosen@aratanarx.com


'/>"/>
SOURCE Aratana Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Aratana Therapeutics Announces $20 Million Financing
2. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
3. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
4. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
5. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. Fate Therapeutics Strengthens Its iPSC Platform
8. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
9. Nile Therapeutics Reports 2011 Third Quarter Financial Results
10. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
11. Orexigen® Therapeutics Reports Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... ... , ... Kapstone Medical is proud to announce that it has ... and inventors develop and safeguard their latest innovations. The company has grown from ... of clients in the United States and around the world. , Company Founder ...
(Date:8/15/2017)... Pittsburgh, PA (PRWEB) , ... August 15, 2017 ... ... JASIS, one of the largest Asian exhibitions for analytical and scientific instruments. This ... Pittsburgh), will be “New Approaches in Mass Spectrometry for Bioanalytical Applications.” This dynamic ...
(Date:8/15/2017)... ... August 15, 2017 , ... Kenall, a ... downlights designed to stay tightly sealed and perform efficiently for years. The downlights ... location listings just aren't enough, such as: hospitals; behavioral health facilities; cleanrooms; containment ...
(Date:8/15/2017)... (PRWEB) , ... August 15, 2017 , ... ... and is threatened by various biotic and abiotic factors. During this educational webinar, ... history of coffee, as well as gain a better understanding of how genomics ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 Research and Markets has announced ... report to their offering. ... global eye tracking market to grow at a CAGR of 30.37% ... Tracking Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
Breaking Biology News(10 mins):